Paradigm Downgrades Biovail (BVF) to Hold
More News related to BVF
- Biovail Announces Closing of Acquisition of Worldwide Rights to Tetrabenazine
- TD Newcrest Upgrades Biovail (BVF) to Action List Buy
- Biovail (BVF) Announces New Increased Revolving Credit Facility
- Biovail Announces New Increased Revolving Credit Facility
- Biovail Announces Pricing of Offering of US$300 Million Senior Convertible Notes due 2014
Paradigm downgrades Biovail Corp. (NYSE: BVF) from Buy to Hold and lowers its price target from $20 to $11.25.
Biovail Corporation, a pharmaceutical company, engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing various drug-delivery technologies in the United States and Canada.
Related Categories
DowngradesStocks Mentioned
+16.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
